Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PLK3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PLK3_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PLK3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PLK3_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PLK3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003157112 | Lung | AIS | mitotic G1 DNA damage checkpoint | 11/1849 | 30/18723 | 7.81e-05 | 1.98e-03 | 11 |
GO:004481911 | Lung | AIS | mitotic G1/S transition checkpoint | 11/1849 | 31/18723 | 1.10e-04 | 2.57e-03 | 11 |
GO:003629313 | Lung | AIS | response to decreased oxygen levels | 53/1849 | 322/18723 | 1.42e-04 | 3.09e-03 | 53 |
GO:003629412 | Lung | AIS | cellular response to decreased oxygen levels | 31/1849 | 161/18723 | 2.15e-04 | 4.36e-03 | 31 |
GO:007145312 | Lung | AIS | cellular response to oxygen levels | 33/1849 | 177/18723 | 2.56e-04 | 4.96e-03 | 33 |
GO:003315712 | Lung | AIS | regulation of intracellular protein transport | 40/1849 | 229/18723 | 2.58e-04 | 4.97e-03 | 40 |
GO:000166613 | Lung | AIS | response to hypoxia | 50/1849 | 307/18723 | 2.79e-04 | 5.26e-03 | 50 |
GO:000703011 | Lung | AIS | Golgi organization | 30/1849 | 157/18723 | 3.09e-04 | 5.63e-03 | 30 |
GO:007145612 | Lung | AIS | cellular response to hypoxia | 29/1849 | 151/18723 | 3.54e-04 | 6.32e-03 | 29 |
GO:00512228 | Lung | AIS | positive regulation of protein transport | 49/1849 | 303/18723 | 3.78e-04 | 6.61e-03 | 49 |
GO:007048213 | Lung | AIS | response to oxygen levels | 54/1849 | 347/18723 | 5.15e-04 | 8.38e-03 | 54 |
GO:000008211 | Lung | AIS | G1/S transition of mitotic cell cycle | 37/1849 | 214/18723 | 5.26e-04 | 8.42e-03 | 37 |
GO:004484311 | Lung | AIS | cell cycle G1/S phase transition | 40/1849 | 241/18723 | 7.43e-04 | 1.07e-02 | 40 |
GO:00447731 | Lung | AIS | mitotic DNA damage checkpoint | 18/1849 | 81/18723 | 7.81e-04 | 1.11e-02 | 18 |
GO:003238612 | Lung | AIS | regulation of intracellular transport | 52/1849 | 337/18723 | 7.89e-04 | 1.11e-02 | 52 |
GO:003112211 | Lung | AIS | cytoplasmic microtubule organization | 14/1849 | 56/18723 | 8.61e-04 | 1.17e-02 | 14 |
GO:19049518 | Lung | AIS | positive regulation of establishment of protein localization | 49/1849 | 319/18723 | 1.21e-03 | 1.54e-02 | 49 |
GO:00447741 | Lung | AIS | mitotic DNA integrity checkpoint | 18/1849 | 85/18723 | 1.41e-03 | 1.73e-02 | 18 |
GO:000007711 | Lung | AIS | DNA damage checkpoint | 22/1849 | 115/18723 | 1.82e-03 | 2.05e-02 | 22 |
GO:001050812 | Lung | AIS | positive regulation of autophagy | 23/1849 | 124/18723 | 2.22e-03 | 2.37e-02 | 23 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLK3 | SNV | Missense_Mutation | | c.1585N>A | p.Leu529Met | p.L529M | Q9H4B4 | protein_coding | tolerated(0.51) | possibly_damaging(0.516) | TCGA-AR-A24M-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | SD |
PLK3 | SNV | Missense_Mutation | | c.1166C>T | p.Ala389Val | p.A389V | Q9H4B4 | protein_coding | tolerated(0.35) | benign(0.001) | TCGA-E2-A1B1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Other, specify in notesbiphosphonate | zoledronic | SD |
PLK3 | insertion | In_Frame_Ins | novel | c.432_433insCGCCGAGCAGGGCGTGGGCACTTGACCCCC | p.Arg144_Lys145insArgArgAlaGlyArgGlyHisLeuThrPro | p.R144_K145insRRAGRGHLTP | Q9H4B4 | protein_coding | | | TCGA-A2-A04Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PLK3 | insertion | Frame_Shift_Ins | novel | c.530_531insAATCCAGGCAGCG | p.His177GlnfsTer23 | p.H177Qfs*23 | Q9H4B4 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLK3 | SNV | Missense_Mutation | novel | c.1543T>C | p.Ser515Pro | p.S515P | Q9H4B4 | protein_coding | tolerated(0.1) | possibly_damaging(0.53) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PLK3 | SNV | Missense_Mutation | | c.512N>T | p.Ser171Phe | p.S171F | Q9H4B4 | protein_coding | deleterious(0) | possibly_damaging(0.506) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PLK3 | SNV | Missense_Mutation | rs755159184 | c.929N>A | p.Arg310His | p.R310H | Q9H4B4 | protein_coding | tolerated(0.09) | benign(0.227) | TCGA-ZJ-AAXD-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
PLK3 | insertion | In_Frame_Ins | novel | c.1910_1911insTACCTG | p.Leu637_Arg638insThrTrp | p.L637_R638insTW | Q9H4B4 | protein_coding | | | TCGA-DS-A1OA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
PLK3 | SNV | Missense_Mutation | novel | c.952N>C | p.Tyr318His | p.Y318H | Q9H4B4 | protein_coding | tolerated(0.05) | possibly_damaging(0.811) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLK3 | deletion | Frame_Shift_Del | | c.1006delN | p.Asn338ThrfsTer35 | p.N338Tfs*35 | Q9H4B4 | protein_coding | | | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | TAE-684 | TAE-684 | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 178102294 | BI-2536 | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | RG-1530 | RG-1530 | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | GW843682X | GW843682X | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | WORTMANNIN | WORTMANNIN | 17135248 |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | LINIFANIB | LINIFANIB | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | GS 6201 | GS 6201 | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | PHA-767491 | CHEMBL225519 | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | inhibitor | 249565601 | ONVANSERTIB | |
1263 | PLK3 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR, ENZYME | | GNF-PF-2301 | CHEMBL578061 | |